The confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request with Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. REDACTED PORTIONS OF...Supply Agreement • May 1st, 2012 • Endo Pharmaceuticals Holdings Inc • Pharmaceutical preparations • New York
This SUPPLY AGREEMENT (this “Agreement”) is made effective as of April 27, 2012 (the “Effective Date”), by and between ENDO PHARMACEUTICALS INC., a corporation organized under the laws of the State of Delaware and having a place of business at 100 Endo Boulevard, Chadds Ford, Pennsylvania, 19317 and all of its subsidiaries and Affiliates (as defined herein) and listed in Exhibit 4 as of the Effective Date (“Company”); and NORAMCO, INC., a Georgia corporation having a place of business at 500 Swedes Landing Road, Wilmington, Delaware 19801 (“Supplier”) (each individually a “Party” and collectively the “Parties”).
The confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities and Exchange Act of 1934, as amended....License and Supply Agreement • May 1st, 2012 • Endo Pharmaceuticals Holdings Inc • Pharmaceutical preparations
WHEREAS, ENDO intends to develop and/or have developed pharmaceutical preparations containing Oxymorphone as the active ingredient and incorporating GRÜNENTHAL’s tamper resistant formulation technology.
